The Swedish sleep apnea registry (SESAR) cohort - "Real world data" on a national level.

The Swedish Sleep Apnea Registry (SESAR) collects clinical data from individual obstructive sleep apnea (OSA) patients since 2010. SESAR has recently been integrated with additional national healthcare data. The current analysis presents the SESAR structure and representative clinical data of a national sleep apnea cohort. Clinical data from unselected patients with a diagnosis of OSA are submitted to the SESAR registry. 48 sleep centers report data from diagnosis, treatment starts with Continuous Positive Airway Pressure (CPAP), oral devices (OD), and Upper Airway Surgery (UAS). Data from follow-up are included. SESAR is linked to mandatory national healthcare data (mortality, comorbidities, procedures, prescriptions) and diagnosis-specific quality registries (e.g. stroke, heart failure, diabetes) within the DISCOVERY project. 83,404 OSA patients have been reported during the diagnostic workup (age 55.4 ± 14.1 years, BMI 30.8 ± 6.5 kg/m SESAR is introduced as a large national registry of OSA patients. SESAR provides a useful tool to highlight OSA management and to perform relevant outcome research.

Informations de copyright

Copyright © 2024. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare participation in the steering committees for the SESAR and/or the Swedevox registries. Outside the submitted work, LG has received unrestricted institutional grants for the ESADA collaboration from RESMED; RESPIRONICS and BAYER AG. LG has lectured for Itamar, Lundbeck, Astra Zeneca, Resmed, and Respironics. LG owns shares of a company which has licensed a patent for pharmacological OSA therapy to Desitin GMBH. Outside the submitted work, ME has received a research grant from ResMed and personal fees from AstraZeneca, Boehringer Ingelheim, Novartis, and Roche. Outside the submitted work, JH has received unrestricted institutional grants for maintenance of the ESADA collaboration from RESMED; RESPIRONICS and BAYER AG. JH has lectured for Itamar, Astra Zeneca, Resmed, and Somnomed. JH is part owner of a company which has licensed a patent for pharmacological OSA therapy to Desitin GMBH.